Is Innospec, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Innospec, Inc. has moved from fair to attractive, indicating a more favorable assessment of its value. The company appears to be undervalued based on its key valuation ratios, which include a P/E ratio of 14, an EV to EBITDA of 10.31, and a PEG ratio of 0.82, all suggesting that the stock is trading at a lower valuation compared to its earnings and growth potential.
In comparison to its peers, Innospec's P/E ratio of 14.56 is lower than Eastman Chemical Co.'s 15.68, while its EV to EBITDA of 10.31 is more competitive than Element Solutions, Inc.'s 14.82. Despite recent underperformance, with a year-to-date return of -32.69% compared to the S&P 500's 13.30%, the attractive valuation metrics suggest that Innospec may present a buying opportunity for investors looking for value in the Chemicals & Petrochemicals sector.